Cell Therapy

Galapagos Shifts Strategy, Considers Selling Cell Therapy Unit
Research & Development Galapagos Shifts Strategy, Considers Selling Cell Therapy Unit

In a bold maneuver to realign its strategic focus, Belgian pharmaceutical firm Galapagos is contemplating the sale of its cell therapy unit, a move that represents a significant departure from its initial restructuring plan. Originally, this unit was poised to become the cornerstone of a strategic

Strong ADCC Activity vs. Minimal ADCC Activity: A Comparative Analysis
Research & Development Strong ADCC Activity vs. Minimal ADCC Activity: A Comparative Analysis

In the ever-evolving landscape of cancer therapies, one of the most significant breakthroughs has been the use of monoclonal antibodies and immune checkpoint inhibitors (ICIs). These therapies aim to enhance the immune system's ability to recognize and eliminate tumors. However, the effectiveness

MiNK's iNKT Therapies Promise Breakthroughs in Cancer Treatment
Research & Development MiNK's iNKT Therapies Promise Breakthroughs in Cancer Treatment

The field of cancer treatment is witnessing seismic shifts as MiNK Therapeutics, a clinical-stage biotechnology firm and subsidiary of Agenus Inc., introduces groundbreaking cell-based therapies focused on treating challenging cancers. With its pioneering work on invariant natural killer T (iNKT)

CMS Launches Model for Greater Access to Gene Therapies
Research & Development CMS Launches Model for Greater Access to Gene Therapies

The Centers for Medicare & Medicaid Services (CMS) has taken a significant step in healthcare innovation by unveiling a pioneering model designed to improve access to advanced treatments for Medicaid patients affected by sickle cell disease. This initiative, focused on the Cell and Gene Therapy

Review of Alyftrek Cystic Fibrosis Therapy
Management & Regulatory Review of Alyftrek Cystic Fibrosis Therapy

In recent years, innovative developments in medical research have led to significant strides in addressing rare genetic disorders like cystic fibrosis (CF). One remarkable advancement is the introduction of Alyftrek, a triple combination therapy approved by the National Institute for Health and

Cell and Gene Therapy Market Expands to $28 Billion by 2030
Biotech & Bioprocessing Cell and Gene Therapy Market Expands to $28 Billion by 2030

The cell and gene therapy (CGT) market is undergoing rapid expansion as it transforms healthcare with innovative treatments for previously incurable diseases. This exhilarating growth is projected to reach $28 billion by the year 2030, marking a significant milestone. Experts attribute this

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later